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Pancreatic cancer  is one of the worst forms of cancer that can 
develop in an individual.  A growing tumor in the pancreas can 
grow for fifteen years before it metastasizes, at which point it 
becomes symptomatic. It is a silent killer growing inside the body. 
Less than 1 % of patients diagnosed with pancreatic cancer sur-
vive even five years, with a median survival of four to six months 
(Warshaw, Fernandez-del Castillo, 1992). Pancreatic cancer is re-
sistant to traditional chemotherapy treatment and therefore even 
once the cancer is detected, the treatment currently available to 
patients is mildly effective at best (Michel, Gress, 2013). 
Surgery, as well has proved only mildly effective. Researchers 
found that less than 10% of patients survived five years after surgi-
cal removal of the tumors. This failure has been attributed to small 
amounts of cells that are left behind that prove to be lethal. In fact, 
28% of patients have been found to have circulating tumor cells in 
the blood and the prevalence increased with the cancer stage (van 
Heerden, et. al. 1981). This would indicate that surgery alone is not 
effective and other treatments should be sought.
Recently, a new chemotherapy (FOLFIRINOX) was proposed 
which showed promising signs, giving patients a longer survival 
time than that associated with the traditional chemotherapies. 
However that advantage didn’t translate into actually curing the 
disease, just prolonging the patients’ lives by a few months. In ad-
dition, this drug showed an increased toxicity, which limited its use 
to only the few patients that can tolerate it (Conroy, et. al. 2011).
It is therefore obvious that new approaches must be sought to-
wards defeating this cancer. Prolonging the lives of its victims is 
not an end goal. Rather, a way of ridding them of the disease al-
together is required. It is therefore obvious that new approaches 
must be sought. Recent research has shown promising results in 
the field of immunology which could indicate some new treat-
ment approaches geared towards eliminating this disease.
Adaptive immunological protection is provided to our bodies via 
two pathways. B cells provide extracellular or humoral immunity 
and create antibodies while T cells provide intracellular or cell 
mediated immunity. Both of these pathways are crucial in order 
for our bodies to be able to fight off even the “simplest” infections. 
If these systems are compromised, even a common cold can prove 
fatal as is evidenced by the HIV virus.
Innate immunity is provided by mechanical barriers such as skin 
and epithelial linings and cellular protection by macrophages, 
other phagocytes and natural killer cells. Macrophages phagocy-
tose antigens into a phogosome and upon receiving signals pro-
vided by certain cytokines, kill the antigens that are engulfed by 
combining the phagosome with a lysosome. The lysosome con-
tains toxic chemicals that can degrade the antigens. Natural killer 
cells respond to infected cells and destroy them before more cells 
become infected.
Adaptive immunity is provided primarily by B cells and T cells. B 
cells create a number of antigen receptors. Some of these receptors 
can be secreted as antibodies and others are attached to the cell 
surface and function as B cell antigen receptors. The first receptor 
that the B cell creates is the IgM receptor, which is closely followed 
by the IgD receptor. These receptors are very specific and can de-
tect sequences of polysaccharides as well as peptide antigens and 
respond to them. The B cells can then produce different antibodies 
depending on the nature of the antigen in order to better combat it. 
The other antibodies that they can produce are IgA, IgE, and IgG. IgA 
is produced in response to mucosal infections and has the ability to 
cross mucous membranes. IgE is primarily produced in response to 
allergens and activates mast cells to release histamine. IgG is one of 
the primary antibodies used to fight infection due to its utilization 
of many mechanisms to assist in destruction of pathogens. It can 
coat antigens (opsonization) in order to assist in their phagocytosis, 
as well as directly neutralizing them by binding to their surface.
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T cells are subdivided into helper T cells and cytotoxic T cells. 
These cells are distinguished by certain biochemical markers on 
their surface. The helper T cell has a CD-4 molecule on its surface, 
while the cytotoxic T cell has a CD-8 molecule on its surface. 
The CD-4 T cell is further subdivided into Th1 helper T cells and 
Th2 helper T cells. The Th1 helper T cell is supportive of a CD-8 
cytotoxic response and help the cytotoxic T cells lyse infected 
cells. However the Th2 helper T cell is not supportive of a CD-8 
cytotoxic response and promotes immune suppression. All T cells 
can only recognize antigen by their T cell receptors if the antigen 
is presented by other cells via a molecule called MHC (Major 
Histocompatibility Complex) which is present on the other cells. 
Certain cells are specialized towards presenting antigen to the T 
cells. This is accomplished by the cell engulfing the foreign material 
(phagocytosis), degrading it and presenting peptide fragments to 
the T cell. The cells that are specialized towards presenting antigen 
are known as antigen presenting cells. These can be dendritic cells, 
B cells and macrophages. Dendritic cells are especially proficient 
at antigen presentation therefore, the presence of mature dendrit-
ic cells is important in order to present the antigen to the T cells. 
The CD-4 helper T cells recognize antigen presented via MHC 
class II which is primarily found only on these specialized antigen 
presenting cells. On the other hand, the CD-8 cytotoxic T cells 
recognize antigen presented by MHC class I which is present on 
almost all cells of the body.
The amazing thing about the immune system is its diversity. 
Because of the various genes that code for the T cell receptors, 
the amount of combinations that the T cell can use is astronom-
ical. Therefore, not only can the receptors be incredibly specific, 
but there can also be a tremendous amount of diversity. The big 
problem that the T cells and the B cells face is how to “know” 
how to react to foreign antigen and not react to self-antigen and 
cause autoimmunity. Autoimmunity is when the immune system 
targets and starts killing the body’s own cells. The way that the 
body solves this problem is by negative selection. This consists 
of a rigorous test that T cells undergo in the Thymus and B cells 
undergo in the bone marrow during development. The cells are 
exposed to self-antigen. If they recognize self-antigen with high 
affinity they undergo apoptosis and are not permitted to mature. 
If however they recognize self-antigen with only low affinity, they 
are permitted to mature and perform their function. 
In addition to regulation at the T cell and B cell development stage, 
there are certain helper T cells that ensure that T cells do not 
react to self-antigen. These are known as regulatory T cells and 
help shut down the T cell response at the end of an adaptive im-
mune response and also ensure that T cells that escaped negative 
selection in the Thymus can be prevented from attacking healthy 
tissue and causing auto-immunity. There are also receptors on the 
T cells themselves that prevent auto-immunity. One of the pri-
mary receptors is the CTLA-4 receptor. When it is engaged, even 
if the T cell is recognizing antigen, the T cell is prevented from 
mounting a response (Abbas, et. al. 2012).
It has been thought since the 1950s that one of the functions of 
the immune system is to prevent the occurrence of cancer in the 
body. This theory is known as immune surveillance. This theory is 
supported by the high incidence of cancer in immune-compro-
mised hosts such as patients with HIV and AIDS (Goedert, et. al. 
1998) as well a high incidence of tumor formation among patients 
taking immunosuppressive medications (Sanchez, et. al. 2002). This 
would indicate that there is some role in the prevention of tu-
mors by the immune system. It has therefore been assumed that 
there must be some antigens that cancerous cells express that are 
recognized by the immune system. In fact many tumor antigens 
have been identified. In some cases the antigens are normal pro-
teins that are usually only present during a particular stage of the 
cell’s life but, because of the tumor are now present during other 
stages as well. They can also be normal proteins that are merely 
over expressed in the cancer cells. Other antigens that have been 
identified are mutated proteins that are present in the diseased 
cell. However, due to the fact that even immune-competent hosts 
have developed cancer, it would seem that the immune system is 
not highly adept at fighting these tumors. Can the immune system 
be induced to fight against pancreatic cancer?
Discussion
Samples of pancreatic tumors from 80 surgically resected tumors 
were studied for signs of immune cell presence, particularly  CD-4 
and CD-8 T- cells. Some patients had one and not the other while 
some had both or none. They noticed that from the patients that 
had both CD-8 and CD-4 T cell infiltration, the overall survival 
rate was much higher than those that were missing one or both of 
these cells. In addition it was apparent that the depth to which the 
cancerous cells were able to penetrate in the pancreas was much 
less for those patients with high levels of both CD-4 and CD-8 
T cells. It would seem that the presence of the T cells indicates 
that the T cells are suppressing the cancerous cells and preventing 
them from infiltrating further. The researchers thus concluded that 
a high level of T cells in the affected pancreas positively correlates 
to an increased survival rate (Fukunaga, et. al. 2004). 
What can be used to attract the T cells? Pancreatic cancer patients 
treated with Interferon alpha after undergoing surgery to remove 
part of the pancreas were studied. Interferon alpha is a cytokine 
produced by the body and is used in the immune response to 
infected cells. When a cell is infected it produces various cyto-
kines that cause downstream signaling. This downstream signaling 
refers to signals that the antigen presenting cells receive by these 
cytokines and increase the antigen presentation to the T cells. This 
is an obvious benefit because additional antigen presentation will 
lead to an increased T cell response. Introducing Interferon alpha 
in addition to the standard chemotherapy increased the length of 
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survival for pancreatic cancer patients. 88% percent of patients 
undergoing the interferon therapy were still alive after two years 
and 55% survived to the five year mark (Tables 1 and 2). This is 
a significant increase as the normal 2 year rate of survival for 
patients being treated with standard chemotherapy alone is 40%. 
The theory is that as interferon is introduced, tumor antigen pre-
sentation is upregulated and therefore more T cells can infiltrate 
the area and fight the cancer. The study noted however that fur-
ther research was still needed (Picozzi, et. al. 2003).
However this study was conducted using patients that had already 
had surgery. Only 20% of pancreatic cancer patients have operable 
tumors and therefore it is apparent that other methods must be 
sought out as well.
Some big drawbacks of using interferon-based chemotherapy are 
the side effects. A recent study of 28 pancreatic cancer patients 
undergoing this treatment showed an increase in toxicity resulting 
in a decrease in white blood cells  (leukopenia) and a decrease 
in neutrophils (neutropenia). Although the toxicity was reversible 
and no patients died, an important consideration is the effect the 
medication has on overall quality of life. The study found that al-
though the overall quality of life decreased, it wasn’t a significantly 
larger decrease than those patients being treated with the stan-
dard chemotherapy. However, it is noteworthy that some of the 
patients being treated with this therapy needed to be hospitalized 
with vomiting, abdominal pain and dehydration (Katz, et. al. 2011).
In response to this systemic toxicity, scientists have proposed 
infecting cancer cells with adenoviruses that express Interferon 
alpha in order to restrict the effects of the interferon localy rather 
than systemically. In studies of other cancers, viruses have been 
shown to exhibit promising effects. The virus can be induced to 
specifically target cancer cells and not healthy cells by using a 
tumor specific promoter called cyclooxygenase 2 which is over 
expressed in cancerous cells. In the case of the adenovirus pro-
posed treatment for pancreatic cancer, after the virally infected 
cell goes through its replication cycle in the infected host cell, 
it produces a “death protein” causing cell death so as to release 
viral particles and infect neighboring cells (Kuruppu, Tanabe, 2005). 
Although previously pancreatic cancer has shown resistance to 
adenoviruses, that has been attributed to a lack of coxsackie-ad-
enovirus receptors on the cell surface. The newly developed ad-
enovirus has been coaxed to bind to alternate cell surface re-
ceptors namely arginine-glycine-aspartic fiber and Ad3 receptor. 
When the virally infected cell dies it releases interferon and can 
thus be contained locally and not cause widespread toxicity and 
dangerous side effects. This treatment thus combats the cancer in 
two ways. The virus itself kills cancerous cells, and the interferon 
Table 1: 
Survival statistics of patients undergoing interferon alpha therapy (Picozzi, et. 
al. 2003).
Table 2:
Survival outcomes for pancreatic cancer patients undergoing various treatments (Picozzi, et. al. 2003).
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that is released induces immunological resistance to the tumor. ( 
Armstrong, et. al. 2012).
There is another problem that must be dealt with in treating any 
cancer using immunotherapy; the problem of immunosuppression. 
As the tumor grows, it changes the local environment from one of 
immunogenicity (favorable to destruction by the immune system) 
to one of immunotolerance (unfavorable to destruction by the 
immune system). As mentioned earlier, CD-8 and CD-4 Th1 T cells 
are extremely important in proper immune function. However as 
the disease progresses there is a larger presence of Th2 T cells, in-
effective CD-8 T cells and perhaps most significantly, an increase in 
regulatory T cells which aid in immune suppression by expressing 
CTLA-4 receptors and secreting immunosuppressive cytokines 
like TGF-β, IL-4 and IL-5 (Ikemoto, et. al. 2006). There is also an 
increase in myeloid derived suppressor cells. These cells suppress 
both the innate and the adaptive immune response (Gabitass, 
et. al. 2011). In addition, rather than there being an infiltration 
of M1 - classically activated macrophages - which phagocytose 
and destroy antigens, there is an infiltration of M2 macrophages 
which are associated with tissue repair. They therefore remodel 
the matrix and in fact enhance the tumor and assist in its growth 
(Schmeider, et. al. 2012) (figure 1). 
Therefore, to truly mount an immunological assault on the cancer, 
these obstacles must be overcome. A way must be found in which 
to cause an infiltration of Th1 helper T cells, classically activat-
ed macrophages and a decrease in the number of regulatory T 
cells and myeloid derived supressor cells in the area of the tumor. 
Recent research has been exploring possible options.
Using antibodies that specifically target the CD-25 marker on 
regulatory T cells, researchers depleted a splenic cell suspension 
containing T cells, of the regulatory T cells within. They injected 
Figure 1. 
Changes in the tumor microenvironment during cancer growth (Sideras, et. al. 2014)
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nude mice (a strain of mice that due to a genetic mutation have no 
thymus and therefore have no T cells), with this sample and later 
with leukemia. They noticed that the tumors first grew and then 
regressed in most of the mice, allowing the mice to live long term 
(more than 80 months). Most of the mice that were injected with 
a non-depleted splenic cell suspension died of the tumor within 
40 days. Furthermore, when the mice were reinjected with larger 
doses of leukemia the immune system mounted an even stron-
ger response and rejected the leukemia much more vigorously. 
This indicated that the mice had become immune to the cancer. 
The conclusion of the researchers was that regulatory T cells pre-
vent other T cells from mounting an immune response. They also 
injected ordinary mice with anti CD-25 antibody and leukemia 
suspensions. These tumors also grew and then regressed within 
1 month in more than 90% of the mice whereas all the control 
mice, injected with ordinary antibodies (not specific to CD-25), 
died within 1 month indicating that even normal mice were able 
to mount a response once the regulatory T cells were depleted 
(Shimizu, et. al. 1999).
It seems that depletion of the CD-25 T cells allows activated, an-
ti-tumor CD-8 and CD-4 T cells to infiltrate and kill the tumor. In 
a clinical trial of breast cancer patients treated with Daclizumab, a 
drug containing anti CD-25 antibodies along with an anti-cancer 
vaccine a marked decrease in CD-25 T cells was observed (Rech, 
Vonderheide, 2009). However at the time of this report only three 
patients were analyzed, and it is therefore premature to declare 
this treatment a success. In addition, Dr. Vonderheide, one of the 
researchers in this clinical trial, declared a potential conflict of 
interest due to his involvement in developing  the included cancer 
vaccine administered along with the Daclizumab. More research 
on pancreatic cancer as well as other cancer patients still needs 
to be conducted before this treatment can be assumed to be 
effective.
However, regulatory T cells have been associated with prevention 
of autoimmunity. Previously, in studies done where T cells were 
removed, autoimmunity was generated. It was, however, unclear 
whether  removing T cells caused autoimmunity because of a lack 
of regulatory T cells or because of a profound lack of any T cells 
which then allowed microbial infections to occur. Recently, how-
ever a study was conducted in which specifically regulatory T cells 
were removed from mice.  Autoimmunity soon developed in var-
ious forms such as diabetes, thyroiditis, and autoimmune gastritis 
(Sakaguchi, et. al. 2001). Any treatment that attempts to eliminate 
regulatory T cells should therefore try to limit the treatment lo-
cally to the site of the tumor or cancerous cells in order to pre-
vent autoimmunity in other parts of the body.
Conclusion 
Although pancreatic cancer is one of the most difficult cancers 
to treat, a multi-pronged approach to treating this disease immu-
nologically would perhaps lengthen the survival time and maybe 
even cure this disease. A possible approach to treating this disease 
could include interferon alpha alone, or virally, in combination with 
anti CD-25 antibodies. This would attract T cells to the site of the 
cancer while at the same time limiting the amount of regulatory 
T cells that ordinarily prevent an anti-cancer response. Care must 
be taken however, to ensure patients do not suffer significant loss 
of quality of life. In addition a balance must be struck between 
eliminating regulatory T cells while still avoiding autoimmunity.
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